IAMOG
LCTX icon

Investors Asset Management of Georgia’s Lineage Cell Therapeutics LCTX Stock Holding History

Investors Asset Management of Georgia’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2
Closed – – 368
2022
Q3 		$0 Hold
2
– – ﹤0.01% 637
2022
Q2 		$0 Buy
+2
New +$3 ﹤0.01% 589

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Investors Asset Management of Georgia's LCTX Position: Q4 2022 in Review

Investors Asset Management of Georgia sold out of Lineage Cell Therapeutics (LCTX) in Q4 2022, closing a stake of 2 shares.

Investors Asset Management of Georgia first reported a position in LCTX in Q2 2022 and held it in 2 quarters. The position peaked at $0 in Q3 2022. 106 funds tracked by Wall St. Rank hold LCTX as of Q4 2022.

  • Investors Asset Management of Georgia reported no remaining Lineage Cell Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Investors Asset Management of Georgia sold 2 Lineage Cell Therapeutics shares in Q4 2022.
  • Investors Asset Management of Georgia first reported a position in Lineage Cell Therapeutics in Q2 2022 and held it in 2 quarters.
  • Investors Asset Management of Georgia's Lineage Cell Therapeutics position peaked at $0 in Q3 2022.
  • 106 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2022.

Based on Investors Asset Management of Georgia's 13F filing for Q4 2022, filed 2 Feb 2023.